Phytochemical and pharmacological profile of Kaduk (Piper sarmentosum Roxb.)

Piper sarmentosum Roxb. (Piperaceae) is a medicinal herb. It is known as ‘kaduk’ and commonly found in subtropical and tropical regions of the world. This plant is traditionally used to cure various ailments and disease such as toothaches, headaches, fever, coughs and asthma. A wide range of phytochemical constituents have been isolated from this plant, including unsaturated amides, flavonoids, lignans, aristolactams, terpenes, steroids, prophenylphenols, alkaloids, long and short chain esters. It is well known to possess many potential bioactivities, for instance, as an antioxidant, anticancer, anti-tuberculosis, antimicrobial, anti-fungal, anti-plasmoid and anti-nociceptive plant. This paper summarizes the information related to the phytochemistry and pharmacology of P. sarmentosum with the description of its botany and traditional uses

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long-term limitation being the eventual need for insulin replacement therapy (Table 1). Since 2007, drugs targeting the glucagon-like peptide-1 (GLP-1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterized even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP-1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand-dependent signalling bias and for a peptide receptor such as the GLP-1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary for future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide. Linked ArticlesThis article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-